Fundraising FoxOCCIDENT — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Immitra Bioimmitrabio.cominJul 2026✓ verified
Immitra Bio develops an in-vivo stem cell therapy platform designed to treat rare genetic diseases, particularly severe inherited red blood cell disorders, by replacing complex transplants with single off-the-shelf treatments.
BiotechDeep TechMedical DevicesZürich, CH
Amir Taheri(Co-founder and Chief Scientific Officer)inJacob Corn(Co-founder and Scientific Advisor)inJan Nelis(Co-founder and Chief Executive Officer)in
Co-investorsKickfundanother.vcBackbone VenturesVenture Kick
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.